This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 1996 Dec 14;348(9042):1668.

doi: 10.1016/S0140-6736(05)65742-X.

Risk of venous thrombosis with hormone replacement therapy

PMID: 8962021
DOI: 10.1016/S0140-6736(05)65742-X

Comment

Risk of venous thrombosis with hormone replacement therapy

M J McKenna. Lancet. 1996.

. 1996 Dec 14;348(9042):1668.

doi: 10.1016/S0140-6736(05)65742-X.

Author

PMID: 8962021
DOI: 10.1016/S0140-6736(05)65742-X

No abstract available

PubMed Disclaimer

Comment on

Risk of venous thrombosis with hormone-replacement therapy.
Vandenbroucke JP, Helmerhorst FM. Vandenbroucke JP, et al. Lancet. 1996 Oct 12;348(9033):972. doi: 10.1016/S0140-6736(05)64918-5. Lancet. 1996. PMID: 8855846 No abstract available.
Risk of venous thromboembolism in users of hormone replacement therapy.
Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Daly E, et al. Lancet. 1996 Oct 12;348(9033):977-80. doi: 10.1016/S0140-6736(96)07113-9. Lancet. 1996. PMID: 8855852
Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.
Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Jick H, et al. Lancet. 1996 Oct 12;348(9033):981-3. doi: 10.1016/S0140-6736(96)07114-0. Lancet. 1996. PMID: 8855853
Prospective study of exogenous hormones and risk of pulmonary embolism in women.
Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Grodstein F, et al. Lancet. 1996 Oct 12;348(9033):983-7. doi: 10.1016/S0140-6736(96)07308-4. Lancet. 1996. PMID: 8855854
Case-control study of venous thromboembolism risk in users of hormone replacement therapy.
Daly E, Vessey MP, Painter R, Hawkins MM. Daly E, et al. Lancet. 1996 Oct 12;348(9033):1027. doi: 10.1016/S0140-6736(96)24041-3. Lancet. 1996. PMID: 8855869 No abstract available.

Similar articles

Risk of venous thrombosis with hormone-replacement therapy.
Vandenbroucke JP, Helmerhorst FM. Vandenbroucke JP, et al. Lancet. 1996 Oct 12;348(9033):972. doi: 10.1016/S0140-6736(05)64918-5. Lancet. 1996. PMID: 8855846 No abstract available.
Hormone replacement therapy is not a risk for venous thrombosis.
Forbes CD, Greer IA. Forbes CD, et al. Scott Med J. 1994 Dec;39(6):165-6. doi: 10.1177/003693309403900602. Scott Med J. 1994. PMID: 8778977 No abstract available.
[Risk of venous thrombosis during postmenopausal estrogen therapy? The reporting system of adverse effects is functioning].
Buajordet I, Dybwad TB. Buajordet I, et al. Tidsskr Nor Laegeforen. 1997 Aug 10;117(18):2644-5. Tidsskr Nor Laegeforen. 1997. PMID: 9324824 Norwegian. No abstract available.
Decision factors influencing hormone replacement therapy.
Rozenberg S, Kroll M, Vandromme J. Rozenberg S, et al. Br J Obstet Gynaecol. 1996 May;103 Suppl 13:92-7; discussion 97-8. Br J Obstet Gynaecol. 1996. PMID: 8624351 Review. No abstract available.
[Estrogens and cardiovascular diseases: should current guidelines be changed?].
Beller F, Theiss W. Beller F, et al. Zentralbl Gynakol. 1994;116(8):441-8. Zentralbl Gynakol. 1994. PMID: 7941812 Review. German.

See all similar articles

Cited by

The adverse effects of hormone replacement therapy.
Tavani A, La Vecchia C. Tavani A, et al. Drugs Aging. 1999 May;14(5):347-57. doi: 10.2165/00002512-199914050-00003. Drugs Aging. 1999. PMID: 10408735 Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.